Share Email Print
cover

Proceedings Paper

Syntheses and cellular studies of water soluble porphyrin-peptide conjugates
Author(s): Martha Sibrian-Vazquez; Timothy J. Jensen; Robert P. Hammer; M. Graça H. Vicente
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Conjugates of meso-tetraphenylporphyrin to the cell targeted NLS SV40 and HIV-1 Tat 48-60 peptide sequences were synthesized on solid-phase using optimized conjugation protocols. Polar groups were introduced at the periphery of the prophyrin macrocycle, and their effect on the in vitro biological performance of the conjugates was evaluated. In vitro biological studies using the new porphyrin conjugates in human HEp2 cells showed that the conjugates bearing the HIV-1 Tat sequence were the most efficiently delivered within cells. The cellular uptake was also dependent on the nature of the substituents at the periphery of the porphyrin macrocycle. On the other hand, the conjugates containing the NLS SV40 peptide sequence and/or hydrophobic groups at the porphyrin periphery were the most phototoxic. The subcellular distribution of the conjugates depended significantly on the nature of the peptide sequence and the overall molecule charge. The conjugates delivered into the more sensitive ER were more phototoxic to the HEp2 cells than those that localized mainly in the lysosomes.

Paper Details

Date Published: 27 February 2007
PDF: 8 pages
Proc. SPIE 6427, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XVI, 64270A (27 February 2007); doi: 10.1117/12.698445
Show Author Affiliations
Martha Sibrian-Vazquez, Louisiana State Univ. (United States)
Timothy J. Jensen, Louisiana State Univ. (United States)
Robert P. Hammer, Louisiana State Univ. (United States)
M. Graça H. Vicente, Louisiana State Univ. (United States)


Published in SPIE Proceedings Vol. 6427:
Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XVI
David Kessel, Editor(s)

© SPIE. Terms of Use
Back to Top